Table 1. Tumor characteristics.
| Simultaneous | Staged | p-value | |
|---|---|---|---|
| Patients | 320 | 109 | |
| Age | 58.6±13.6 | 59.4±12.3 | 0.60 |
| Female | 150 (46.9%) | 41 (37.6%) | 0.10 |
| Comorbidities | 194 (60.6%) | 61 (56.0%) | 0.69 |
| Colon primary | |||
| Right | 58 (18.1%) | 14 (12.8%) | p=0.38 |
| Transverse | 23 (7.2%) | 4 (3.7%) | |
| Left | 18 (5.6%) | 9 (8.2%) | |
| Sigmoid | 78 (24.4%) | 29 (26.7%) | |
| Rectum | 143 (44.7%) | 53 (48.6%) | |
| pT 3/4 | 269 (84.1%) | 91 (84.3%) | 1.00 |
| pN 1/2 | 191 (59.7%) | 65 (59.6%) | 1.00 |
| LNN density | 14.1±20.9% | 13.1±18.6% | 0.66 |
| Hepatic metastases | |||
| Size | 3.6±3.2cm | 5.4±3.5cm | <0.01 |
| Number of lesions | 2.1±1.3 | 2.2±1.2 | 0.75 |
| ≥5 lesions | 48 (15.0%) | 10 (9.2%) | 0.15 |
| Fong Score | 2.5±0.9 | 2.8±0.6 | <0.01 |
| Neoadjuvant therapy | |||
| Chemo | 125 (39.1%) | 29 (26.6%) | p=0.13 |
| Chemoradiation | 42 (13.0%) | 14 (12.8%) | |
| Radiation only | 4 (1.3%) | 9 (8.3%) | |
| None | 149 (46.6%) | 57 (52.3%) | |
pT, pathological tumor size; pN, pathological regional lymph node involvement; LNN, lymph node. Hepatic metastases are reported by histopathological assessment.